11. Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancerSimona Borštnar, Tanja Čufer, Ivan Vrhovec, Zvonimir Rudolf, 1999, original scientific article Abstract: Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2.
Published in DiRROS: 22.01.2024; Views: 166; Downloads: 41
 Full text (548,70 KB) |
12. The urokinase-type plasminogen activator, its inhibitors and its receptor - the new prognostic factors in solid cancersSimona Borštnar, Tanja Čufer, Zvonimir Rudolf, 1997, review article Abstract: The urokinase-type plasminogen activator (uPA), its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR) play nan important role in the degradation of the intercellular tissue, the process which affects the ability of cancer cells to invade to surrounding tissue and to metastasize. The results of clinical studies performed in the past few years point out a significant influence of uPA, PAI-1, PAI-2 and uPAR on the course of the disease and survival of patients with solid tumours, particularly breast cancer. Hopefullythe categorization of patients according to the content of the serineproteases and its inhibitors in tumour tissues could provide a basis formore rational treatment planning and thus improving patients' survival.
Published in DiRROS: 18.01.2024; Views: 140; Downloads: 40
Full text (485,80 KB) |
13. |
14. |
15. |
16. Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in miceMaja Čemažar, Damijan Miklavčič, Lojze Vodovnik, Tomaž Jarm, Zvonimir Rudolf, Borut Štabuc, Tanja Čufer, Gregor Serša, 1995, original scientific article Keywords: neoplasmas, experimental therapy, cisplatin, electric stimulation therapy, cell membrane permeability
Published in DiRROS: 15.01.2024; Views: 137; Downloads: 39
Full text (393,12 KB) |
17. Prognoza netipljivih invazivnih rakov dojkeTanja Čufer, 2004, published scientific conference contribution Abstract: Izhodišča. Neodvisni napovedni dejavniki poteka raka dojk na podlagi katerih danes načrtujemo dopolnilno sistemsko zdravljenje so prizadetost pazdušnih bezgavk, velikost tumorja, patohistološki tip tumorja in stopnja malignosti tumorja. Z ozaveščanjem in z uvedbo presejalnih programov se odkriva vse več majhnih, netipljivih rakov dojk. Medtem ko so napovedni dejavniki poteka tipljivih rakov dojk dobro znani, so napovedni dejavniki poteka netipljivih invazivnih rakov dojk veliko manj raziskani. Zaključki. Sistemskih analiz napovednega pomena posameznih lastnosti tumorjev pri netipljivem invazivnem raku dojk praktično ni. Napovedni pomen za ponovitev bolezni in za preživetje ima še vedno velikost tumorja in biološka lastnost tumorja, stopnja malignosti. Tudi prisotnost mikrozasevkov v pazdušnih bezgavkah, glede na omejene podatke, verjetno napoveduje slabo prognozo. Starost in prisotnost hormonskih receptorjev se zaenkrat nista izkazala za neodvisen napovedni dejavnik poteka bolezni pri majhnih tumorjih. Da bi bolje opredelili prognozo bolnic z majhnimi, netipljivimi raki dojk in jih ustrezneje zdravili, je nujnarazpoznava dodatnih bioloških značilnosti raka dojk. Genska karta tumorjadoločena s tehnologijo mikromrež je obetavna metoda, ki omogoča širok vpogled v biologijo vsakega posameznega raka dojke.
Published in DiRROS: 01.12.2023; Views: 151; Downloads: 46
Full text (310,72 KB) |
18. Elektrokemoterapija malignega melanomaGregor Serša, Borut Štabuc, Tanja Čufer, Boris Jančar, Damijan Miklavčič, Maja Čemažar, Zvonimir Rudolf, 1999, published scientific conference contribution Keywords: melanom, zdravljenje, bleomicin, cisplatin, električna stimulacija, elektrokemoterapija, elektroporacija, melanoma therapy, bleomycin, cisplatin, electric stimulation therapy, electrochemotherapy, electroporation
Published in DiRROS: 27.11.2023; Views: 174; Downloads: 60
Full text (617,96 KB) |
19. Potek in prognoza raka dojkTanja Čufer, 1998, review article Abstract: Rak dojk je napogostejša vrsta raka pri ženskah. Medtem ko je bila bolezen še v začetku tega stoletja neozdravljiva, danes s kombinacijo kirurškega, obsevalnega in sistemskega zdravljenja ozdravimo več kot polovico bolnic. Na prognozo in potek raka dojk značilno vpliva razširjenost oziroma stadij bolezni ob začetku zdravljenja. Bolnice z večjimi tumorji in še zlasti bolnices prizadetimi pazdušnimi bezgavkami imajo slabši izid bolezni. Na potekbolezni in prognozo vplivajo še druge lastnosti tumorja, na primer patohistološka vrsta s stopnjo malignosti, navzočnost hormonskih receptorjev, poliferativna sposobnost celic in drugo. Na potek in izid bolezni značilno vpliva tudi zdravljenje. Sodobne kirurške tehnike, ki jih kombiniramo z obsevanjem, omogočajo boljšo lokalno kontrolo bolezni ob manj obsežnih kirurških posegih. Pri več kot polovici bolnic je danes mogoče ohraniti dojko.Dopolnilna sistemska terapija ob lokalnem zdravljenju omogoča boljšo sistemsko kontrolo bolezni in značilno izboljša preživetje bolnic z operabilnim rakom dojk. Metastatski rak dojk je danes še vedno neozdravljiva bilezen, vendar pa je bolezen mogoče zazdraviti za daljše časovno obdobje. Pričakujemo, da bosta uvedba novih, učinkovitejših načinov zdravljenja in odkrivanje bolezni v zgodnejših stadijih še naprej izboljševala prognozo bolnic z rakom dojk.
Published in DiRROS: 24.11.2023; Views: 188; Downloads: 70
Full text (272,98 KB) |
20. |
